The UK Prospective Diabetes Study (UKPDS) is the most important trial ever conducted in type 2 diabetes. Published in The Lancet in 1998 with a landmark 10-year post-trial follow-up published in the New England Journal of Medicine in 2008, UKPDS established several pillars of modern care: glycemic control reduces microvascular complications in proportion to A1C reduction, metformin uniquely benefits overweight patients with no weight gain or excess hypoglycemia, blood pressure control matters as much as glucose control, and intensive treatment confers lasting “legacy” benefits long after the original trial.
Background: Why UKPDS Was Needed
Before UKPDS, the role of intensive glucose lowering in type 2 diabetes was unclear. The DCCT had answered the question for type 1 diabetes in 1993, but type 2 diabetes differs fundamentally — older patients, higher cardiovascular risk, insulin resistance rather than absolute deficiency, and a different complication profile. Observational data suggested A1C mattered, but a definitive randomized trial was missing. The UK Medical Research Council and several UK foundations funded UKPDS, which began enrolling in 1977 and ran until 1997 — 20 years that yielded an unmatched data set.
Trial Design
| Design Feature | Detail |
|---|---|
| Trial type | Multicenter randomized controlled trial |
| Years | 1977 to 1997 (median 10 years follow-up) |
| Participants | 5,102 newly diagnosed adults with type 2 diabetes |
| Age at entry | 25 to 65 years |
| Mean A1C at randomization | ~7 percent (after 3-month dietary run-in) |
| Intensive arm | Sulfonylurea (chlorpropamide, glibenclamide) or insulin; target fasting glucose below 108 mg/dL |
| Conventional arm | Diet alone unless symptomatic hyperglycemia; pharmacotherapy added if FBG above 270 |
| Metformin substudy | 753 overweight patients randomized to metformin within the intensive arm |
| BP substudy | 1,148 hypertensive patients randomized to tight (less than 150/85) vs less tight (less than 180/105) BP control |
| Achieved A1C: intensive | ~7.0 percent |
| Achieved A1C: conventional | ~7.9 percent |
| Primary outcomes | Composite of diabetes-related endpoints, diabetes-related deaths, all-cause mortality |
Primary Glucose Control Results
The intensive group achieved a sustained 0.9 percentage point lower A1C over the 10-year follow-up. This relatively modest difference still produced meaningful clinical benefits:
| Outcome | Intensive vs Conventional | Risk Reduction | P value |
|---|---|---|---|
| Any diabetes-related endpoint | Reduced | 12 percent | 0.029 |
| Microvascular endpoints (composite) | Reduced | 25 percent | 0.0099 |
| Retinopathy progression | Reduced | 21 percent | 0.015 |
| Photocoagulation requirement | Reduced | 29 percent | 0.003 |
| Microalbuminuria at 12 years | Reduced | 33 percent | 0.000054 |
| Myocardial infarction | Trend toward reduction | 16 percent | 0.052 |
| Stroke | No significant difference | — | NS |
| All-cause mortality | No significant difference | — | NS |
| Major hypoglycemia per year | Increased | ~3 times higher | — |
UKPDS established the epidemiological relationship: every 1 percentage point reduction in A1C corresponded to approximately a 35 percent reduction in microvascular complications, 18 percent in MI, 17 percent in stroke, and 25 percent in diabetes-related deaths.
The Metformin Substudy
Within the intensive arm, 753 overweight patients (BMI above 27) were randomized to metformin rather than sulfonylurea or insulin. The results were striking and changed clinical practice globally:
| Outcome (Metformin vs Conventional) | Risk Reduction | P value |
|---|---|---|
| Any diabetes-related endpoint | 32 percent | 0.0023 |
| Diabetes-related death | 42 percent | 0.017 |
| All-cause mortality | 36 percent | 0.011 |
| Myocardial infarction | 39 percent | 0.01 |
| Stroke | 41 percent | 0.13 |
| Weight gain | None vs +4 to 6 kg in other intensive arms | — |
| Major hypoglycemia per year | No excess | — |
Metformin matched the A1C reduction of sulfonylurea or insulin but added cardiovascular and mortality benefits that the other agents did not — without weight gain or excess hypoglycemia. This is why metformin remains the global first-line type 2 diabetes drug nearly three decades later, only recently joined (but not displaced) by SGLT2 inhibitors and GLP-1 receptor agonists in specific high-risk populations.
The Blood Pressure Substudy
Among the 1,148 hypertensive UKPDS participants, tight BP control to below 150/85 (achieved mean 144/82) was compared with less tight control (achieved mean 154/87). The 9 mmHg systolic and 5 mmHg diastolic difference produced large benefits:
- 24 percent reduction in any diabetes-related endpoint
- 32 percent reduction in diabetes-related deaths
- 44 percent reduction in stroke
- 37 percent reduction in microvascular complications
- 34 percent reduction in retinopathy progression
UKPDS estimated that every 10 mmHg decrease in systolic BP was associated with about a 12 percent reduction in diabetes-related complications. The BP findings, combined with the glucose findings, established the dual-target approach that defines modern type 2 diabetes care.
The Legacy Effect (UKPDS 10-Year Follow-up)
UKPDS continued post-trial observational follow-up for 10 additional years. As in DCCT/EDIC, the two groups’ A1Cs converged quickly. Yet the original intensive group continued to fare better:
- 9 percent continued reduction in any diabetes-related endpoint
- 15 percent continued reduction in myocardial infarction
- 13 percent continued reduction in death from any cause
- 24 percent continued reduction in microvascular endpoints
The metformin group’s benefit was even more durable: 33 percent reduction in MI and 27 percent reduction in all-cause mortality persisted at 10-year follow-up. This UKPDS legacy effect, like DCCT’s glycemic memory, argues strongly for treating glucose intensively from diagnosis rather than waiting until complications appear.
What UKPDS Did Not Show
- It did not demonstrate a stroke reduction with glucose control (BP control did)
- It did not enroll older adults above age 65, limiting direct applicability to that population
- It did not test SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or thiazolidinediones — these came later and required their own trials
- It did not show that A1C below 6.5 percent further reduces cardiovascular events (later answered by ACCORD, which found harm at very tight control in high-CV-risk patients)
- It used older sulfonylureas; modern sulfonylureas and other agents may have different profiles
How UKPDS Shapes Modern Care
- Metformin first-line: Standard of care globally for type 2 diabetes initiation
- A1C targets near 7 percent: Direct translation of intensive-arm A1C
- Dual treatment targets: Glucose AND blood pressure, each independently important
- Early intensification: Legacy effect argues for tight control at diagnosis
- Treatment intensification ladders: Modern guidelines build on UKPDS-era stepwise additions but now add SGLT2i and GLP-1 RA earlier in high-risk patients
- Individualization for older or sicker patients: Hypoglycemia trade-offs require softer targets in vulnerable populations
Implications for Patients and Clinicians
UKPDS demonstrates that type 2 diabetes is treatable in the same way DCCT demonstrated treatability for type 1 diabetes. A 1 percentage point reduction in A1C — easily achievable with metformin, lifestyle changes, or modern medications — meaningfully reduces eye, kidney, and nerve complications, plus cardiovascular events with metformin specifically. The blood pressure substudy adds that a 10-point systolic BP drop is equally protective. The combination is powerful: patients who hit both glucose and BP targets accumulate large risk reductions across the cardiovascular, microvascular, and mortality spectrum.
Related Reading
See our broader guides on diabetes treatment, the DCCT trial (type 1 diabetes), the ACCORD trial, and the EMPA-REG OUTCOME trial.
The Bottom Line
The UKPDS trial established the foundations of type 2 diabetes care. Every 1 percentage point of A1C reduction cut microvascular complications by about 35 percent. Metformin uniquely reduced cardiovascular events and mortality in overweight patients, making it the global first-line drug. Tight blood pressure control (mean 144/82 vs 154/87) reduced diabetes-related deaths by 32 percent and stroke by 44 percent. The 10-year post-trial legacy effect showed sustained benefit decades after groups’ A1Cs converged. UKPDS underpins today’s A1C-near-7-percent target, the dual glucose-and-BP treatment approach, and the argument for early intensive treatment at diagnosis. It remains, with DCCT, the most influential clinical trial in diabetes history.
